| 1 |
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med, 2004, 351(17): 1731-1740.
|
| 2 |
Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial[J]. Lancet, 2009, 373(9666): 811-820.
|
| 3 |
van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial[J]. Lancet Oncol, 2011, 12(6): 575-582.
|
| 4 |
Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study[J]. Lancet Oncol, 2014, 15(2): 184-190.
|
| 5 |
Mathis KL, Larson DW, Dozois EJ, et al. Outcomes following surgery without radiotherapy for rectal cancer[J]. Br J Surg, 2012, 99(1): 137-143.
|
| 6 |
Kinugasa T, Akagi Y, Ochi T, et al. Lateral lymph-node dissection for rectal cancer: meta-analysis of all 944 cases undergoing surgery during 1975-2004[J]. Anticancer Res, 2013, 33(7): 2921-2927.
|
| 7 |
Stipa F, Zernecke A, Moore HG, et al. Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection? [J]. Ann Surg Oncol, 2004, 11(2): 187-191.
|
| 8 |
Read TE, Andujar JE, Caushaj PF, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status[J]. Dis Colon Rectum, 2004, 47(6): 825-831.
|
| 9 |
Pucciarelli S, Capirci C, Emanuele U, et al. Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer[J]. Ann Surg Oncol, 2005, 12(2): 111-116.
|
| 10 |
Perez RO, Habr-Gama A, Lynn PB, et al. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution[J]. Dis Colon Rectum, 2013, 56(1): 6-13.
|
| 11 |
Perez RO, Habr-Gama A, Proscurshim I, et al. Local excision for ypT2 rectal cancer--much ado about something[J]. J Gastrointest Surg, 2007, 11(11): 1431-1438; discussion 1438-1440.
|
| 12 |
Callender GG, Das P, Rodriguez-Bigas MA, et al. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer[J]. Ann Surg Oncol, 2010, 17(2): 441-447.
|
| 13 |
Garcia-Aguilar J, Shi Q, Thomas CR Jr, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial[J]. Ann Surg Oncol, 2012, 19(2): 384-391.
|
| 14 |
Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis[J]. Ann Surg Oncol, 2012, 19(9): 2822-2832.
|
| 15 |
Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients[J]. Int J Radiat Oncol Biol Phys, 2008, 72(1): 99-107.
|
| 16 |
Lambregts DM, Maas M, Bakers FC, et al. Long-term follow-up features on rectal MRI during a wait-and-see approach after a clinical complete response in patients with rectal cancer treated with chemoradiotherapy[J]. Dis Colon Rectum, 2011, 54(12): 1521-1528.
|
| 17 |
Glynne-Jones R, Wallace M, Livingstone JI, et al. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? [J]. Dis Colon Rectum, 2008, 51(1): 10-19; discussion 19-20.
|
| 18 |
Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer[J]. J Clin Oncol, 2011, 29(35): 4633-4640.
|
| 19 |
Glynne-Jones R, Hughes R. Critical appraisal of the 'wait and see' approach in rectal cancer for clinical complete responders after chemoradiation[J]. Br J Surg, 2012, 99(7): 897-909.
|
| 20 |
Perez RO, Habr-Gama A, Pereira GV, et al. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? [J]. Colorectal Dis, 2012, 14(6): 714-720.
|
| 21 |
Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients[J]. J Am Coll Surg, 2002, 194(2): 131-135; discussion 135-136.
|
| 22 |
Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy[J]. Ann Surg, 2012, 256(6): 965-972.
|
| 23 |
Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control[J]. Int J Radiat Oncol Biol Phys, 2014, 88(4): 822-828.
|
| 24 |
Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? [J]. Dis Colon Rectum, 2013, 56(10): 1109-1117.
|
| 25 |
Garcia-Aguilar J, Smith DD, Avila K, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial[J]. Ann Surg, 2011, 254(1): 97-102.
|
| 26 |
Gao YH, Zhang X, An X, et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer[J]. Strahlenther Onkol, 2014, 190(2): 158-164.
|
| 27 |
Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study[J]. J Clin Oncol, 2010, 28(5): 859-865.
|
| 28 |
Samuelian JM, Callister MD, Ashman JB, et al. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 82(5): 1981-1987.
|
| 29 |
Li JL, Ji JF, Cai Y, et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial[J]. Radiother Oncol, 2012, 102(1): 4-9.
|
| 30 |
Tryggvason G, Gíslason HG, Magnússon MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study[J]. Int J Cancer, 2005, 117(2): 289-293.
|
| 31 |
Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study[J]. BMC Cancer, 2007, 7: 230.
|
| 32 |
Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden[J]. Cancer, 2005, 103(4): 821-829.
|
| 33 |
Monges G, Bisot-Locard S, Blay JY, et al. The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists[J]. Bull Cancer, 2010, 97(3): E16-22.
|
| 34 |
Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal[J]. Am J Pathol, 1998, 152(5): 1259-1269.
|
| 35 |
Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis[J]. Lancet Oncol, 2009, 10(11): 1045-1052.
|
| 36 |
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2009, 373(9669): 1097-1104.
|
| 37 |
Eisenberg BL. The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors[J]. Am J Clin Oncol, 2013, 36(1): 89-90.
|
| 38 |
McCarter MD, Antonescu CR, Ballman KV, et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence[J]. J Am Coll Surg, 2012, 215(1): 53-59; discussion 59-60.
|
| 39 |
Group EESNW. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23 Suppl 7: vii49-55.
|
| 40 |
Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors[J]. J Natl Compr Canc Netw, 2010, 8 Suppl 2: S1-41; quiz S42-4.
|
| 41 |
Tielen R, Verhoef C, van Coevorden F, et al. Surgical management of rectal gastrointestinal stromal tumors[J]. J Surg Oncol, 2013, 107(4): 320-323.
|
| 42 |
Jakob J, Mussi C, Ronellenfitsch U, et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib[J]. Ann Surg Oncol, 2013, 20(2): 586-592.
|
| 43 |
Fujimoto Y, Akiyoshi T, Konishi T, et al. Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum[J]. Int J Colorectal Dis, 2014, 29(1): 111-116.
|
| 44 |
Hohenberger P, Oladeji O, Licht T, et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST) [J]. J Clin Oncol, 2009, 27(15S): 10550.
|
| 45 |
Hohenberger P, Eisenberg B. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST) [J]. Ann Surg Oncol, 2010, 17(10): 2585-2600.
|
| 46 |
Centonze D, Pulvirenti E, Pulvirenti D'Urso A, et al. Local excision with adjuvant imatinib therapy for anorectal gastrointestinal stromal tumors[J]. Tech Coloproctol, 2013, 17(5): 571-574.
|